

10/089583

PCT/PTO 11 JUL 2002

10/25/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Joyce S. Plested et al.
Serial No. : 10/089,583
Filed : March 28, 2002.
PCT Appln. No.: PCT/GB00/03758
PCT Filing Date: 2 October 2000
Title : VACCINE

Art Unit : Unknown
Examiner : Unknown

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the specification:

Paragraph beginning at page 19, line ¹⁵~~16~~ has been amended as follows:

SR
5/12/01
A1
--Figure 10a illustrates ELISA titres of antibodies to *L3 gale* LPS (IgG) in paired sera taken early and late from children with invasive meningococcal disease, and Figure 10b illustrates means % phagocytosis of *Neisseria meningitidis* MC58 with paired sera taken early and late from children with invasive meningococcal disease with human peripheral blood mononuclear cells and human complement; --

Paragraph beginning at page 55, line 7 has been amended as follows:

A2
--We present data on three paired sera taken from infants early (acute) and later (convalescent) during culture confirmed invasive meningococcal disease (IMD) that resulted from infection with *Neisseria meningitidis* isolates of immunotypes L1, L3 (MAb b5 reactive) (patients 1 and 2) and L2 immunotype (MAb B5 non-reactive) (patient 3) (Figures 10a and 10b).

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 943803619 US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202.

Date of Deposit July 11, 2002

Signature Henry Jenkins

Typed or Printed Name of Person Signing Certificate

APPLICANT (S): PLESTED, Joyce S. et al.
SERIAL NO.: 10/089,583
FILED: July 11, 2002
Page 2

In the Specification:

Please amend page 1, line 2, as follows:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a National Stage Application under 371 of PCT/GB00/03758, filed 10/02/00, now abandoned, which claims priority of U.S. Provisional Application 60/196,305, filed 4/12/00 and U.S. Provisional Application 60/156,940, filed 09/30/99, which are hereby incorporated by reference.

5/12/09
Please insert the following on page 18, line ²⁶~~27~~:

Brief Description of the Drawings

Please amend page 18, fourth full paragraph, as follows:

Figures 1a-1b illustrate[[s]] the LPS structure of various *Neisseria meningitidis* immunotypes;

Please amend page 19, line 4, as follows:

Figures 3a-3c illustrate[[s]] molecular models of the calculated (MMC) lowest energy states of the core oligosaccharide from *galE* mutants of L3, L4, and L8 dephosphorylated;

Please amend page 19, line 10, as follows:

Figures 5a-5d illustrate[[s]] confocal immunofluorescence microscopy of *Neisseria meningitidis* organisms strain MC58 adherent to HUVECs;

APPLICANT (S): PLESTED, Joyce S. et al.
SERIAL NO.: 10/089,583
FILED: July 11, 2002
Page 3

Please amend page 19, line 13, as follows:

Figures 6a-6b illustrate[[s]] silver stained tricine gels of LPS preparations from group B strains not reactive with B5;

Please amend page 19, line 16, as follows:

Figures 7a-7d illustrate[[s]] accessibility of the LPS epitope to A4 in *Neisseria meningitidis* whole cells;

Please amend page 20, line 23, as follows:

Figures 15a-15b illustrate[[s]] a FACS profile comparing surface labeling of live *Neisseria meningitidis* MC58 and *galE* mutant (5 x 10⁸ org/ml) with MAb (culture supernatant 1:50) detected using anti-mouse IgG (FITC labeled).

Please amend page 46, first full paragraph, as follows:

Figures 1a-1b

Please amend page 46, fifth full paragraph, as follows:

Figures 3a-3c

Please amend page 47, third full paragraph, as follows:

Figures 5[.])a[.])-5d

Please amend page 47, fifth full paragraph, as follows:

Figures 6a-6b

Please amend page 50, ninth full paragraph, as follows:

See Figures 7a-7d.

Seventh
Please amend page 51, ~~sixth~~ full paragraph, as follows:

See Figures 3a-3c.

SP
5/12/09

APPLICANT (S): PLESTED, Joyce S. et al.
SERIAL NO.: 10/089,583
FILED: July 11, 2002
Page 4

Please amend page 59, second full paragraph, as follows:

Figures 15a-15b. FACS profile comparing surface labeling of live *Neisseria meningitidis* MC58 and *galE* mutant (5×10^8 org/ml) with MAb (culture supernatant 1:50) detected using anti-mouse IgG (FITC labeled).

S12
5/12/09

Please amend page 46, line ²~~1~~, as follows:

Representation of the structure of meningococcal LPS oligosaccharides of immunotypes L1 to L9. Immunotypes are indicated to the extreme left. The vertical line marks the junction between the inner core structures to the right and outer core structures to the left. The epitope recognized by MAb B5 is ~~indicated in boldface~~ underlined (MAb B5 positive). Arabic numerals indicate the linkage between sugars or amino sugars. Alpha and beta indicate the carbon 1 linkage at the nonreducing end of the sugar. Genes for incorporating each of the key sugars or amino sugars into the LPS oligosaccharide in the biosynthetic pathway are indicated with arrows indicating where in the pathway the gene product is required. Abbreviations: Kdo, 2-keto-2-deoxyoctulosonic acid; Gal, galactose; GlcNAc, N-acetylglucosamine; Glu, glucose; Hep, heptose. Immunotype L5 has no PEtn on the second heptose. The gene that adds the glucose to the second heptose (IgtG) is phase variable.

Please amend page 27, third full paragraph, as follows:

A solid-phase indirect ELISA with purified LPS was used to determine the binding specificities of MAbs. Nunc Maxisorp® plates were coated overnight with 1.0 µg of purified LPS per well derived from wild-type and mutants. LPS (10 µg/ml) was diluted in 0.05 M carbonate buffer containing 0.02 M MgCl₂ (pH 9.8). Nonspecific binding sites were blocked for 1 h with 1% BSA-PBS (Sigma) and washed three times with PBS-Tween® 20 (0.05% [vol/vol]; PBS-T). Plates were incubated for 1 h with MAb B5 culture supernatant and washed three times in PBS-T. Primary antibody was detected with anti-mouse IgG-alkaline phosphatase (Sigma and Cedarlane Laboratories, Ltd.) incubated for 1 h, washed three times in PBS-T, and detected with p-nitrophenyl phosphate alkaline phosphatase substrate system

APPLICANT (S): PLESTED, Joyce S. et al.
SERIAL NO.: 10/089,583
FILED: July 11, 2002
Page 5

(Sigma and Kirkegaard & Perry Laboratories). The reaction was stopped after 1 h with 50 µl of 3 M NaOH, and the absorbance ($A_{405-410}$) was determined (Dynatech EIA plate reader

Please amend page 28, third full paragraph, as follows:

Whole cell (WC) ELISA was performed by using heat-inactivated lysates of *N. meningitidis* organisms as described previously (Abdillahi, H., and J. T. Poolman. 1988. J. Med. Microbiol. 26:177-180). Nunc Maxisorp® 96-well plates were coated with 100 µl of bacterial suspension (optical density [OD] of 0.1 at A_{620}) overnight at 37°C and blocked with 1% BSA-PBS; an identical protocol was followed as for LPS ELISA.

5/12/09
Please amend page 53, ^{second} full paragraph, as follows:

Briefly, fluorescently labeled ethanol fixed *Neisseria meningitidis* MC58 or *galE* mutant or beads coated with purified *galE* LPS (10ug/ml) were opsonized with MAb B5 and human complement source diluted in final buffer for 10mins/37C/ 500rpm in microtitre plate. Then human peripheral blood polymorphonuclear cells (MPMs) prepared from heparinised donor blood were diluted in final buffer and added to each well (1×10^7 cells/ml) and incubated for a further 10mins/37C/ 500rpm. Reaction mixture was stopped on ice by addition of 150 µl PBS-EDTA and added to FACS tube containing 50 µl Trypan Blue®. Mixture was mixed and 10,000 lymphocytes were analyzed on FACScan and Cellquest software. PMs were analyzed by FSC vs appropriate channels to determine % uptake of fluorescent bacteria by granulocytes and monocytes (% OP activity).

Please amend page 54, second full paragraph, as follows:

(5) Affinity purified MAb B5. Spent culture supernatant from MAb B5 was purified on Protein A-sepharose® column and eluted with Glycine pH 4.5, neutralised with Tris-HCl pH 9.0. Fractions were tested for reactivity on LPS ELISA, pooled and concentrated using Amicon®-filter. Purity was determined by SDS-PAGE gel and protein concentration was determined by OD and protein assay.